Increased expression of costimulatory markers CD134 and CD80 on IL-17 producing T-cells in patients with systemic lupus erythematosus

Sebastian Dolff1,2*, Daniel Quandt1*, Benjamin Wilde1, Thorsten Feldkamp1, Fan Hua1, Xin Cai1, Christof Specker3, Andreas Kribben1, Cees G.M. Kallenberg2, Oliver Witzke1

1 Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, The Netherlands
2 Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Germany these authors contributed equally
3 Department of Rheumatology and Clinical Immunology, Kliniken Essen Süd, Germany

Abstract

Objectives: There is growing evidence that interleukin-17 (IL-17) producing T-cells are involved in the pathogenesis of systemic lupus erythematosus (SLE). Previous studies showed that increased percentages of T-cell subsets expressing the costimulatory molecules CD80 and CD134 are associated with disease activity and renal involvement in SLE. The aim of this study was to investigate the distribution and phenotypical characteristics of IL-17 producing T-cells in SLE, in particular in patients with lupus nephritis, with emphasis on the expression of CD80 and CD134.

Patients and Methods: Thirty-four patients (3 male, 31 female, mean age 41 ±15 years) fulfilling at least four of the American College of Rheumatology (ACR) revised criteria for the diagnosis of SLE and 24 healthy controls were enrolled. T-cells from the peripheral blood were analysed by fluorescence activated cell sorting (FACS) for their expression levels of CD80, CD134 and CCR6. In vitro stimulated CD3^+IL17^+ cells were also investigated for the expression of these costimulatory markers. Finally, renal biopsies from SLE patients were evaluated for the presence of CD134 expressing T-cells.

Results: Percentages of IL-17 expressing T-cells were significantly increased in patients with active disease as compared to healthy controls (1.46 ±0.58 % versus 0.93 ±0.30 %, p=0.007). The percentage of IL-17 producing T-cells was correlated with disease activity as assessed by systemic lupus erythematosus disease activity index (SLEDAI) (r=0.53, p=0.003). In patients, most of the IL-17 producing T-cells were confined to the CCR6^+ T-cell subset (80 ±13 %). Expression of CD80 and CD134 on the IL-17 producing T-cell subset was higher in SLE than in healthy controls (HC) (CD134: 71.78 ±14.51 % versus 51.45 ±16.58 %, p=0.002; CD80: 25.5 ±14.99 % versus 14.99 ±5.74 %, p=0.02). Also, patients with lupus nephritis expressed higher levels of CD134^+ on CD3^+IL-17^+ cells as compared to HC (72.69 ±11.54 % versus 51.45 ±16.58 %, p=0.006). Furthermore, renal biopsies of lupus nephritis patients showed infiltration of CD134^+ T cells.
**Conclusion:** Percentages IL-17 expressing T-cells correlate with disease activity. Further, these cells show increased expression of costimulatory markers such as CD134 and CD80. The presence of CD134⁺ T-cells in renal biopsies of lupus nephritis patients suggest that these cells migrate to the kidney and might contribute to inflammatory processes through IL-17 secretion.
Introduction

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease characterized by an imbalanced T-cell homeostasis with a shift towards activated effector T-cell subsets. Two major subsets of CD4^+ T helper cells, Th1 and Th2, have been shown to be involved in the pathogenesis of SLE. Th1 cells secrete interferon gamma (INF-γ) and are induced by IL-12, whereas Th2 cells secrete IL-4, IL-5 and IL-13 and are induced by IL-4.\(^1\)\(^2\)

More recently, another subset of cytokine producing T-cells, so called Th17 cells producing the cytokine IL-17, were described. IL-17 exerts its function through recruiting neutrophils and monocytes, upregulating local chemokine expression, facilitating T-cell migration into tissues, and inducing immune responses.\(^3\)\(^-\)\(^6\) There is increasing evidence that IL-17 producing T-cells play an important role in various autoimmune diseases including multiple sclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, ANCA associated vasculitis and systemic lupus erythematosus.\(^7\)\(^-\)\(^11\)

Recent studies demonstrated the importance of IL-17 produced by different T-cell subsets such as CD4^+ T-cells, CD8^+ T-cells, CD3^-CD4^-CD8^- T-cells, and γδ T-cells in human SLE.\(^12\)\(^-\)\(^13\) Furthermore, Yang et al. reported an association of IL17-producing T-cells and clinical features as disease activity assessed by systemic lupus erythematodes disease activity index (SLEDAI).\(^14\)

Studies investigating the role of IL-17 producing T-cells in the pathogenesis of lupus nephritis (LN) are rare. However, studies in mice support the idea that IL-17 may contribute to renal disease, in particular lupus nephritis.\(^14\)\(^-\)\(^17\) Crispin et al. demonstrated infiltration of IL-17^+ double negative T-cell in kidneys of lupus nephritis patients. More recently, single-cell analysis of laser-microdissected lupus nephritis sections showed a skewing towards IL-17.\(^18\) Further evidence comes from urine analysis in lupus nephritis patients where IL-17 gene expression was inversely correlated with disease activity.\(^19\) These studies demonstrated the pivotal role of IL-17 cells in the pathogenesis of lupus nephritis. In humans an overwhelming amount of IL-17 cells express the
chemokine receptor CCR6. Therefore, CCR6 might be a useful phenotypic marker for the analysis of IL-17 T-cells.

Previously, we reported an association of increased levels of costimulatory markers on CD4+ cells with lupus nephritis. Especially, expression of CD134 was associated with disease activity and renal involvement, but a functional analysis of these CD134 expressing cells is still lacking. As a member of the tumour necrosis factor (TNF) superfamily, CD134 (OX40) provides co-stimulatory signals upon ligation to the CD134 Ligand. Moreover, it is possible that CD134+ T-cells infiltrate kidneys and cause inflammation after ligation with CD134L which has been shown to be present on glomerular endothelial cells in SLE patients. Thus, CD134 might be a pivotal surface marker to enable effector cell migration towards the kidney. The significance of CD134 for effector functions has been shown by the observation that treatment with a stimulatory anti-CD134 antibody enhances T-cell expansion and differentiation to effector cells in mice. This stimulation, apparently, promotes the secretion of IFN-γ and the upregulation of various interleukin (IL)-receptors with might lead subsequently to cytokine-mediated kidney cell damage. Remarkably, increased percentages of CD134 expressing T-cells as well as Th17 cells have been found amongst effector cells in several autoimmune diseases such as Wegener’s Granulomatosis, rheumatoid arthritis and myasthenia gravis.

To elucidate the role and phenotype of IL-17 producing effector T-cells in patients with systemic lupus erythematosus, in particular with lupus nephritis, we investigated their presence and phenotypic characteristics in the present study. We analysed not only peripheral blood but also tissue from patients with lupus nephritis. We tested the hypothesis that increased expression of costimulatory molecules on these cells may promote their infiltrations into the kidney due to interaction with ligands on resident renal cells.
Patients and methods

Study population
34 patients (3 male, 31 female, mean age 41 ±15 years) fulfilling at least four of the American College of Rheumatology (ACR) revised criteria for the diagnosis of SLE and 24 healthy controls (mean age 46 ±14 years) were enrolled in the study. 13 patients had lupus nephritis (WHO class II: 2 patients, class III: 1 patient, class IV: 5 patients, class V: 4 patients, unclassified: 2 patients) while 22 patients had no clinical evidence of lupus nephritis (absence of proteinuria and/or glomerular hematuria). Clinical disease activity at the time of measurement was assessed according to the systemic lupus erythematous disease activity index (SLEDAI) (mean SLEDAI 4 ±5). Patients with a SLEDAI ≥ 4 were defined as active, 19 active and 15 inactive patients were included into the study. 26 patients were treated with prednisone (mean 27 ±91 mg/d), 8 patients were without prednisone, and 23 patients were on a constant dose of immunomodulating drugs (azathioprine (n=8), mycophenolate mofetil (n=10), cyclosporine A (n=2), hydroxychloroquine (n=9), leflunomide (n=1), rituximab (n=2)), 2 patients had no medication at the time of the study. 13 patients had been treated with cyclophosphamide (mean dose: 2003 ±4193 mg) during their disease course. Consecutive patients were included from the University Hospital of Essen and the Medical Center Essen Süd. The study protocol was approved by the institutional review board. All patients gave informed consent for participation in this study.

Flow cytometry
Expression level of the surface molecules on lymphocytes was assessed by four-colour surface staining. Phycoerythrin (PE), fluorescein isothiocyanate (FITC), peridin chlorophyll protein (PerCP) and Allophycocyanin (APC)-labelled antibodies were used: CD3 (mouse IgG1, PerCP), CD4 (mouse IgG1, PerCP), CD8 (mouse IgG1 FITC), CCR6 (mouse IgG1, FITC), CD134 (mouse IgG1, PE), CD80 (mouse IgG1, PE, R&D Systems, Wiesbaden, Germany) and IL-17 (mouse IgG1, APC). All antibodies were purchased from Becton Dickinson,
Heidelberg, Germany, except for IL-17, purchased from eBioscience, San Diego, USA, and CCR6 purchased from R&D Systems, Minneapolis, USA. Appropriate isotype controls (Becton Dickinson, Heidelberg) were used. Briefly, peripheral blood was stained with labelled monoclonal antibodies for 20 min in the dark at room temperature. The cell suspension was incubated with lysis buffer for 15 min and prepared as indicated. Analysis was performed with a fluorescence activated cell sorter (FACS) Calibur™ from Becton Dickinson.

**Immunostaining for intracellular cytokines**

Peripheral blood mononuclear cells (PBMCs) of patients were separated by standard Ficoll-Paque density gradient centrifugation. The cells were resuspended in RPMI 1640 medium (Gibco BRL, Karlsruhe, Germany) supplemented with 10 % heat inactivated fetal calf serum (Biochrom, Berlin, Germany). The cells were cultured in the absence or presence of PMA (5 ng/ml) and Ionomycin (1 µM) (Sigma-Aldrich, Seelze, Germany) for 5 hours. Cytokine secretion was inhibited by Brefeldin A (Ebioscience, Frankfurt, Germany). Then surface staining was performed with CD3, CD134, CD80, CCR6 and appropriate isotype controls. Cells were fixed and permeabilized by using a Cytofix/Cytoperm kit purchased from Becton Dickinson (Heidelberg, Germany). Finally, the samples were intracellularly stained with IL-17 or an appropriate isotype control.

**Immunohistochemistry**

Renal biopsies were provided by the Institute of Pathology University Hospital of Essen. Specimens were fixed in 10 % neutral buffered formaline and paraffin-embedded. 5 µm thick sections were deparaffinized in xylene and rehydrated in a series of ethanol with different concentrations (100 %, 95 %, 70 % and 50 %). Citrate buffer pH 6.0 (Zytomed, Berlin) was applied for heat induced epitope retrieval, followed by neutralization of endogenous peroxidase with 0.3 % H₂O₂. Primary antibodies (CD3 obtained from DCS, Hamburg, Germany and CD134 obtained from Becton Dickinson) and HRP-conjugated secondary antibodies
(Zytomed) were incubated on slides (each for 30 minutes) at room temperature. Washing with PBS was performed after each incubation step. A DAB substrate Kit (Zytomed) was used for visualization. Finally, the slides were slightly counterstained with hematoxylin.

**Immunofluorescence double staining**
Tissues were fixed, embedded in paraffin and sectioned as indicated above. Epitope retrieval was performed with citrate buffer pH 6.0 (Zytomed). Primary antibodies against CD3 (rabbit IgG1, DCS) and CD134 (mouse IgG1, Becton Dickinson) were used and incubated for 60 minutes at room temperature simultaneously. Secondary antibodies conjugated to Cy2 and Cy3 (Dianova, Hamburg) were applied for 30 minutes. Finally, the slides were mounted with Immuno Mount™ (Thermo Fisher, Kehl).

**Statistics**
All values are expressed as mean ±SD. Significance for the differences between groups was determined by the Mann-Whitney U-test. Spearman’s rank correlation test was applied for detecting correlations between different study parameters. A p value less than 0.05 was considered significant.
Results

Expression of CCR6 and phenotypic features of CCR6+ peripheral blood CD4+ cells

In order to characterise IL-17 producing cells with a suitable marker expressed on the surface we analysed T-cells for the expression of CCR6. Peripheral blood circulating CD4+CCR6+ cells were analysed in 28 patients and 11 healthy individuals. There were no differences in the percentages of CD4+CCR6+ cells between patients with SLE and healthy controls (19.74 ±8.57 % vs. 16.97 ±5.67 %, p=0.34). Furthermore, there were no significant differences between active (n=10) and inactive (n=18) patients (18.63 ±8.01 % vs. 20.36 ±9.04 %, p=0.46) or between patients with or without lupus nephritis (22.39 ±8.05 % vs. 17.86 ±8.08 %, p=0.24). There were also no differences in of CCR6 expression between patients with and without lupus nephritis and healthy controls (22.39 ±8.05 % vs. 16.97 ±5.67 % and 17.86 ±8.08 % vs. 16.97 ±5.67 %, p=0.08 and p=0.76, respectively). Active and inactive patients showed no difference in levels of CCR6+ cells as compared to healthy controls (18.63 ±8.01 % vs. 16.97 ±5.67 % and 20.36 ±9.04 % vs. 16.97 ±5.67 %, p=0.6 and p=0.31, respectively).

The CCR6+ subset was analysed for the expression of costimulatory markers CD80 and CD134. Remarkably, percentages of CD134 and CD80 expressing CCR6+ cells were significantly increased in patients with SLE in comparison to healthy controls (CD134: 67.87 ±12.23 % vs. 59.27 ±8.18 %, p=0.02; CD80: 26.46 ±12.28 % vs. 13.86 ±3.82 %, p=0.001).

Expression of costimulatory markers CD134 and CD80 on CD4+CCR6+ cells in active and inactive patients and patients with and without lupus nephritis

Patients with and without active disease as assessed by SLEDAI, and patients with and without lupus nephritis proven by renal biopsy, were analysed for CD80 expression on CD4+CCR6+ cells. The percentages of CD80 expressing on CD4+CCR6+ cells showed no difference between active and inactive patients
There was a significant difference between inactive SLE patients and healthy controls (28.06 ±11.07 % vs. 13.86 ±3.82 %, p=0.0006). Expression of CD80 on CD4^+CCR6^+ cells in active patients tended to be increased as compared to healthy controls (23.58 ±13.41 % vs. 13.86 ±3.82 %, p=0.062). Patients with lupus nephritis showed significantly higher levels of CD80 expression on CD4^+CCR6^+ cells in comparison to healthy controls (22.13 ±10.58 % vs. 18.86 ±3.82 %, p=0.02). The same applied for patients without lupus nephritis (30.66 ±12.75 % vs. 18.86 ±3.82 %, p=0.0009). Comparing patients with lupus nephritis and patients without lupus nephritis no difference could be observed (22.13 ±10.58 % vs. 30.66 ±12.75 %, p=0.11).

Expression of CD134 on CD4^+CCR6^+ cells was significantly higher in patients with inactive disease compared to healthy controls (70.89± 10.35 % vs. 59.27 ±8.18 %, p=0.0097) but not different from active patients (70.89± 10.35 % vs. 62.14 ±14.16 %, p=0.17). Patients with lupus nephritis expressed higher levels of CD134 on peripheral blood CD4^+T^+cells as compared to HC (68.08 ±7.52 % vs. 59.27 ±8.18 %, p=0.027). Patients without lupus nephritis showed no difference in comparison to patients with lupus nephritis and healthy individuals (67.75 ±13.46 % vs. 68.08 ±7.52 % p=0.91; 67.75 ±13.46 % vs. 59.27 ±8.18 %, p=0.05).

**SLE Patients with active disease show increased levels of IL-17 producing T-cells in peripheral blood**

The percentage of IL-17 producing T-cells was analysed in the peripheral blood of 30 SLE patients and 16 healthy controls. There was no significant difference between SLE patients and healthy controls (1.17 ±0.61 % vs. 0.93 ±0.30 %; p=0.37). Patients with active disease had significantly elevated levels of IL-17 expressing T-cells in the peripheral blood in comparison to healthy controls (1.46 ±0.58 % vs. 0.93 ±0.30 %, p=0.007). Active patients had also increased levels of IL17^+ T-cells as compared to inactive patients. (1.46 ±0.58 % vs. 0.88
±0.5 %, p=0.002) (Figure 1). The expression of IL-17 within CD8 cells revealed an expression of 0.9 ±0.5 % (n=5).

Figure 1. (a) Percentages of IL-17 producing CD3⁺ cells in patients with SLE (n=30) and healthy controls (HC) (n=16). (b) A representative two colour immunofluorescence dot plot of CD3⁺ cells showing expression levels of IL-17 from an SLE patient and a healthy control. Cells positive for both antibodies are represented in the right upper quadrant with the percentage indicated. (c) Percentages of IL-17 producing CD3⁺ cells in active patients (n=15), inactive patients (n=15) and healthy controls (n=16). (d) Percentages of IL-17 producing CD3⁺ cells in patients with lupus nephritis (with LN) (n=13), patients without lupus nephritis (without LN) (n=14) and healthy controls (n=16). Data are presented as mean value. Significance was tested by the Mann-Whitney U-test. A p value less than 0.05 was considered significant.


**Ex vivo IL-17 production of CD3⁺ cells correlates with disease activity and is independent of renal involvement**

The percentage of IL-17 producing CD3⁺ cells correlated significantly with disease activity (p=0.003, r=0.53) (Figure 2). To study the influence of medication we compared the proportion of IL-17 expressing cells in patients on prednisone alone versus patients on a combination of immunosuppressants. There was no difference between these groups. This observation could be confirmed in a follow-up in 12 patients. Changes over time (21 ±13 weeks) of IL-17 expression were associated with changes in disease activity (r=0.81, p=0.001). Expression of IL-17 in patients with lupus nephritis (n=13) was not different as compared to patients without lupus nephritis (n=14) (1.29 ±0.65 % vs. 1.08 ±0.57 %, p=0.34). A subanalysis revealed also no difference regarding the expression of IL-17 between patients with a class IV LN and patients with class V (0.94 ±0.53% vs. 1.62 ±0.94%, p=0.25). There was also no association with other histological features. Further, there was no correlation between expression of IL-17 and anti-dsDNA titres or complement levels. Patients with lupus nephritis showed no difference to healthy controls (0.93 ±0.30 %, p=0.15).

**Phenotypic features of IL-17⁺ T-cells in patients with SLE**

The expression of costimulatory markers CD80 and CD134 was analysed within the IL17⁺ subset in patients and healthy controls. The percentages of CD134 and CD80 expressing IL17 producing T-cells were significantly increased in SLE patients in comparison to healthy controls (CD134: 71.78 ±14.51 % vs. 51.45 ±16.58 %, p=0.002; CD80: 25.5 ±14.99 % vs. 14.99 ±5.74 %, p=0.02) (figure 3a and b). A subanalysis in SLE patients (n=5) showed that only 1.7 ±1.8 % IL-17 producing T-cells were double positive for CD80 and CD134. There was no significant correlation between the proportion of CD134 and CD80 and IL-17 expression (p=0.8 and p=0.6, respectively).
CD134+ IL-17 producing T-cells in lupus nephritis

Figure 2. Correlation between percentages of IL-17 producing T-cells for all samples taken (n=30) and disease activity as assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Spearman analysis was performed to calculate the correlation. A p value less than 0.05 was considered significant.

Figure 3. (a) Percentages of CD80+ IL-17 producing CD3+ cells in patients with SLE (n=30) and healthy controls (HC) (n=13). (b) The expression of CD134+ on IL-17 producing CD3+ cells from patients with SLE (n=30) and healthy controls (HC) (n=13). (c) Percentages of CD80+ and CD 134+ IL-17 producing T-cells form active (n=15) and inactive (n=15) patients with SLE and healthy controls (n=13). (d) Expression of CD80+ and CD 134+ on IL-17 producing T-cells from patients with lupus nephritis (with LN) (n=13), patients without lupus nephritis (without LN) (n=14) and healthy controls (n=13). Data are shown as mean value. Significance was tested by the Mann-Whitney U-test. A p value less than 0.05 was considered significant.
Expression of costimulatory markers CD134 and CD80 on IL17-producing T-cells in active and inactive patients and patients with and without lupus nephritis

Patients with and without active disease were analysed for CD80 expression on IL-17 producing T-cells. The percentages of CD80 expressing IL-17 producing T-cells showed no differences between active and inactive patients (25.02 ±16.01 % vs. 25.97 ±14.46 %, p=0.87). There was a significant difference between inactive SLE patients and healthy controls (25.97 ±14.46 % vs. 14.99 ±5.74 %, p=0.02). Expression of CD80 on IL-17 producing T-cells in active patients tended to be increased as compared to healthy controls (25.02 ±16.01 % vs. 14.99 ±5.74 %, p=0.07). Patients were further analysed based on the presence of lupus nephritis. Patients with and without lupus nephritis showed significantly higher levels of CD80 expression on IL17+ cells as compared to healthy controls (26.71 ±15.85 % and 26.90 ±15.06 % vs. 14.99 ±5.74 %, p=0.04 and p=0.02, respectively). There was no difference in the expression of CD80 on IL17+ cells between patients with and without lupus nephritis (26.71 ±15.85 % vs. 26.90 ±15.06 %, p=0.85) (Figure 3c and d). No significant difference could be observed comparing the expression of CD80 on IL-17 producing T-cells in patients with class IV and V lupus nephritis (36.25 ±18.66 % vs. 21.93 ±9.18 %, p=0.63). Interestingly, there was a correlation between CD80 expression on IL-17 producing T-cells and anti-dsDNA titres and decreased C3 levels, respectively (r=0.6, p=0.0003 and r=-0.5, p=0.01).

Expression of CD134 on IL-17 producing T-cells was significantly higher in patients with active disease as compared to healthy controls (74.87 ±10.64 % vs. 51.54 ±16.58 %, p=0.0009). Also in patients with inactive disease expression of CD134 on IL-17 producing T-cells was higher as compared to healthy controls (68.69 ±17.39 % vs. 51.45 ±16.58 %, p=0.0382), but it did not differ from active patients (68.69 ±17.39 % vs. 74.87 ±10.64 %, p=0.34). Patients with lupus nephritis expressed higher levels of CD134 on peripheral T-cells as compared to healthy controls (72.69 ±11.54 % vs. 51.45 ±16.58 %, p=0.0056). Patients without lupus nephritis also showed higher levels of CD134.
on IL-17 producing T-cells in comparison to healthy individuals (70.27 ±17.18 % vs. 51.45 ±16.58 %, p=0.01). No difference could be observed between patients with and without lupus nephritis (72.69 ±11.54 % vs. 70.27 ±17.18 %, p=0.91) (Figure 3d). Further, expression of CD134 on IL-17 producing T-cells showed no significant differences between class IV and V lupus nephritis (69.05 ±10.97 % vs. 78.27 ±6.51 %, p=0.23).

Immunohistochemistry (IHC) staining for CD134 in inflamed tissue

To determine whether CD134⁺ T-cells were present in inflammed organs of SLE patients, four renal biopsies were stained for CD134 and CD3. CD134⁺ cells were located within or in the neighbourhood of small vessels and tubulointerstitial lymphocyte infiltrates. Single cells were found around glomeruli. Serial sections revealed a colocalization with CD3⁺ T-cells; this could be confirmed by immunofluorescent double staining with CD3 and CD134 (Figure 4).

Figure 4 (a) Representative renal biopsy of an SLE patient with lupus nephritis (WHO class IV). The biopsy was stained for CD134 using immunohistochemistry. (b) Staining of the biopsy for CD3⁺ and CD134⁺ cells by immunofluorescence. CD3 (A), CD3/DAPI (B), CD134 (C) and colocalization of CD134 with CD3 (D).
Discussion

The results of this study suggest that IL-17 producing cells play a pivotal role in the pathogenesis of systemic lupus erythematosus. In vitro stimulated CD3⁺ cells from active SLE patients produced significantly higher levels of IL-17 as compared to healthy controls. Remarkably, only T-cells isolated from active patients produced higher levels of IL-17 than controls. The association between IL-17 production and disease activity was further supported by a significant correlation of IL-17 expression and disease activity as assessed by SLEDAI. These findings are in accordance with a large previous study by Yang et al. in which 50 patients were enrolled. In addition, Wong et al. demonstrated increased circulating plasma concentrations of IL-17 in SLE patients as compared to healthy controls. In contrast to our study a correlation of plasma levels of IL-17 and disease activity could only be found in patients without renal disease. Both studies lack a detailed subanalysis of patients with and without lupus nephritis. Therefore, a subanalysis was performed on the presence of lupus nephritis in this study. Patients with biopsy proven lupus nephritis were compared to patients without renal involvement. However, a significant difference in the amount of IL17-producing peripheral CD3⁺ cells could not be found between these groups which could be related to the rather small size and heterogeneous composition of this group of biopsy proven lupus nephritis patients. Moreover, the impact of immunosuppressive drugs remains uncertain although we found no difference in patients on prednisone versus patients with a combination of immunosuppressive drugs regarding either IL-17 expression nor expression of costimulatory molecules (data not shown). There is growing evidence in murine models that IL-17 plays a crucial role in the pathogenesis of renal diseases such as lupus nephritis. These results can be explained by the hypothetical migration of IL-17 cells into inflamed kidneys.

The present study reveals that IL-17 cells express significantly higher amounts of the costimulatory markers CD80 and CD134. Ex vivo stimulation has been shown to upregulate the expression of CD134 over time but the significant difference between active patients and controls seem to be
associated with disease activity according to our findings. In addition, we detected CD134+ T-cells in lupus nephritis biopsies. These findings have been confirmed by Zhou et al. in a larger analysis of 40 kidney biopsies. Possibly, in humans these CD134+ T-cells infiltrate the kidney after ligation with CD134L expressed by endothelial cells which could subsequently lead to IL-17 mediated renal injury. Blocking CD134/CD134Ligand interaction as a therapeutic intervention has been successfully used in lupus mice. However, the role of IL-17 has not been investigated in that study. Interestingly, a recent report investigating the influence of CD134/CD134Ligand interaction on IL-17 cytokine production suggests that IL-17 production is downregulated after ligation of CD134. This could be interpreted as a negative feedback loop for the effector function of CD134+ cells but the detailed mechanisms remain unclear. An important regulatory role of Th17 cells through the CD28/CD80 pathway was also discussed in a murine model.

Taken together we demonstrated that IL-17 producing cells are closely linked to disease activity in SLE patients and express high levels of the costimulatory markers CD80 and CD134. These new subsets of IL-17 cells might be important in human lupus nephritis. The presence of CD134+ T-cells in renal biopsies of lupus nephritis patients suggest that these cells migrate to the kidney and might contribute to inflammatory processes through IL-17 secretion. Further studies are necessary to dissect pathogenic role of IL-17 in lupus in order to establish IL-17 as a therapeutic target in SLE.
Chapter 4

References


